XYA01 / XYone Therapeutics - LARVOL DELTA

Targeting MUC1 in advanced genitourinary malignancies: Expression landscape, molecular correlates, and preclinical activity of novel antibody-drug conjugates in prostate and bladder cancers (ESMO 2026) - "Across all evaluated xenograft models, MUC1-directed ADCs (XYA01 and XYA02) demonstrated robust antitumor activity, resulting in significant tumor growth inhibition and tumor regression. Importantly, therapeutic activity was observed even in established, larger tumors with lower antigen expression, highlighting the potential of this approach in advanced disease settings.Conclusions Our findings establish MUC1 as a frequently expressed and therapeutically actionable target in advanced bladder cancer and a molecularly defined subset of prostate cancers, particularly those with low PSMA expression. Collectively, this work provides a strong rationale for the clinical development of MUC1-targeted ADCs and for biomarker-driven patient stratification in advanced genitourinary malignancies."

ADC • Metastases • Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1 • MUC1